Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced it has executed a term sheet with arm's-length institutional investors for a previously announced non-brokered private placement with a notional subscription amount of approximately CAD$5 million. The offering, consisting of 6,764,070 units at a notional price of CAD$0.7392 per unit, is expected to close on or about July 15, 2026, subject to customary conditions and regulatory approvals. Each unit comprises one common share and one common share purchase warrant.
The company stated that proceeds from the financing are intended to support development of its ONC010 program, including manufacturing and preclinical testing activities, advancement of its SynoGraph platform, and general working capital. Under the proposed structure, the company's economic interest will be determined through 18 monthly settlement tranches based on the future trading price of its shares, with additional details to be provided upon closing.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors.
The announcement is significant as it provides Onco-Innovations with the necessary capital to advance its pipeline, particularly the ONC010 program and SynoGraph platform. The non-dilutive structure of the placement, with settlement based on future share prices, may align investor interests with company performance. The successful closing of this placement could accelerate preclinical development and manufacturing, potentially moving the company closer to clinical trials.
For more details, the full press release is available at https://ibn.fm/y3hsM. Updates on the company can be found in its newsroom at https://ibn.fm/ONNVF.
